{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:47:36Z","timestamp":1790884056467,"version":"4.1.0"},"reference-count":34,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2023.2625","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T06:33:30Z","timestamp":1676961210000},"source":"Crossref","is-referenced-by-count":4,"title":["Early variation of inflammatory indexes refines prognostic prediction in patients with hepatocellular carcinoma under systemic treatment"],"prefix":"10.3892","volume":"18","author":[{"given":"Leonardo","family":"Da Fonseca","sequence":"first","affiliation":[{"name":"Department of Oncology, ICESP - Institute of Cancer of Sao Paulo, University of Sao Paulo School of Medicine, 01246\u2011000 Sao Paulo\u2011SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Uratani","sequence":"additional","affiliation":[{"name":"Department of Oncology, ICESP - Institute of Cancer of Sao Paulo, University of Sao Paulo School of Medicine, 01246\u2011000 Sao Paulo\u2011SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Soares","sequence":"additional","affiliation":[{"name":"Department of Oncology, ICESP - Institute of Cancer of Sao Paulo, University of Sao Paulo School of Medicine, 01246\u2011000 Sao Paulo\u2011SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Do Amaral","sequence":"additional","affiliation":[{"name":"Department of Oncology, ICESP - Institute of Cancer of Sao Paulo, University of Sao Paulo School of Medicine, 01246\u2011000 Sao Paulo\u2011SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regiane","family":"De Souza Melo Alencar","sequence":"additional","affiliation":[{"name":"Sao Paulo Cl\u00ednicas Liver Cancer Group, University of S\u00e3o Paulo School of Medicine, 01246\u2011000 Sao Paulo\u2011SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Chagas","sequence":"additional","affiliation":[{"name":"Sao Paulo Cl\u00ednicas Liver Cancer Group, University of S\u00e3o Paulo School of Medicine, 01246\u2011000 Sao Paulo\u2011SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venancio","family":"Alves","sequence":"additional","affiliation":[{"name":"Sao Paulo Cl\u00ednicas Liver Cancer Group, University of S\u00e3o Paulo School of Medicine, 01246\u2011000 Sao Paulo\u2011SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flair","family":"Carrilho","sequence":"additional","affiliation":[{"name":"Sao Paulo Cl\u00ednicas Liver Cancer Group, University of S\u00e3o Paulo School of Medicine, 01246\u2011000 Sao Paulo\u2011SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"key20230317120437_b1-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"key20230317120437_b2-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"key20230317120437_b3-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20230317120437_b4-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"key20230317120437_b5-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"key20230317120437_b6-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"key20230317120437_b7-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20230317120437_b8-MCO-18-4-02625","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"key20230317120437_b9-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"109484","key":"key20230317120437_b10-MCO-18-4-02625","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109484","article-title":"Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice","volume":"135","author":"Rimola","year":"2021","journal-title":"Eur J Radiol"},{"key":"key20230317120437_b11-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jhep.2021.05.015","article-title":"Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma","volume":"75","author":"Kolamunnage-Dona","year":"2021","journal-title":"J Hepatol"},{"key":"key20230317120437_b12-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41575-019-0179-x","article-title":"Insights into the success and failure of systemic therapy for hepatocellular carcinoma","volume":"16","author":"Bruix","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20230317120437_b13-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"key20230317120437_b14-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"key20230317120437_b15-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"issue":"dju124","key":"key20230317120437_b16-MCO-18-4-02625","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"key20230317120437_b17-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy-development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J Hepatol"},{"key":"key20230317120437_b18-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2016.10.010","article-title":"Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer","volume":"49","author":"Luen","year":"2017","journal-title":"Pathology"},{"issue":"264","key":"key20230317120437_b19-MCO-18-4-02625","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0264-5","article-title":"Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"31","author":"da Fonseca","year":"2014","journal-title":"Med Oncol"},{"key":"key20230317120437_b20-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies","volume":"67","author":"Bruix","year":"2017","journal-title":"J Hepatol"},{"key":"key20230317120437_b21-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"key20230317120437_b22-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","article-title":"Tumor-Associated neutrophils recruit macrophages and T-Regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib","volume":"150","author":"Zhou","year":"2016","journal-title":"Gastroenterology"},{"key":"key20230317120437_b23-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/0008-5472.CAN-13-1186","article-title":"Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: Role of IL-15R\u03b1 and NKG2D triggering","volume":"74","author":"Romero","year":"2014","journal-title":"Cancer Res"},{"key":"key20230317120437_b24-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"key20230317120437_b25-MCO-18-4-02625","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00245-6","article-title":"Hepatocellular carcinoma","volume":"7","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"key20230317120437_b26-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"key20230317120437_b27-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: From tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev"},{"key":"key20230317120437_b28-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: Functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"key20230317120437_b29-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri3442","article-title":"The integration of T cell migration, differentiation and function","volume":"13","author":"Masopust","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"key20230317120437_b30-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","article-title":"Neutrophils escort circulating tumour cells to enable cell cycle progression","volume":"566","author":"Szczerba","year":"2019","journal-title":"Nature"},{"key":"key20230317120437_b31-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1073\/pnas.1320753111","article-title":"Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients","volume":"111","author":"Wu","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20230317120437_b32-MCO-18-4-02625","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer","volume":"166","author":"Almand","year":"2001","journal-title":"J Immunol"},{"issue":"1225","key":"key20230317120437_b33-MCO-18-4-02625","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01225","article-title":"Peripheral leukocytosis is inversely correlated with intratumoral CD8+ T-Cell infiltration and associated with worse outcome after chemoradiotherapy in anal cancer","volume":"8","author":"Martin","year":"2017","journal-title":"Front Immunol"},{"issue":"202","key":"key20230317120437_b34-MCO-18-4-02625","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0431-3","article-title":"Relevance of tumor-infiltrating lymphocytes in breast cancer","volume":"13","author":"Dushyanthen","year":"2015","journal-title":"BMC Med"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T06:04:46Z","timestamp":1679033086000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2023.2625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2,21]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2023.2625","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]},"article-number":"29"}}